Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Why Plug Power Inc.'s Shares Popped in July (and Dropped in August)
Why Plug Power Inc.'s Shares Popped in July (and Dropped in August)
Shares of Plug Power Inc. (NASDAQ: PLUG) jumped 10.8% in July, according to data from S&P Global Market Intelligence, after the company announced an expanded agreement with Wal-Mart (NYSE: WMT). The
Why Plug Power Inc.'s Shares Popped in July (and Dropped in August)
Why Plug Power Inc.'s Shares Popped in July (and Dropped in August)
Shares of Plug Power Inc. (NASDAQ: PLUG) jumped 10.8% in July, according to data from S&P Global Market Intelligence, after the company announced an expanded agreement with Wal-Mart (NYSE: WMT). The
Elon Musk Should Tell the Truth, the Whole Truth, and Nothing but the Truth
Elon Musk Should Tell the Truth, the Whole Truth, and Nothing but the Truth
During its brief history, Tesla (NASDAQ: TSLA) has missed many self-imposed deadlines to bring products to market. It has also routinely fallen short of its annual production goals. These shortcomings
Elon Musk Should Tell the Truth, the Whole Truth, and Nothing but the Truth
Elon Musk Should Tell the Truth, the Whole Truth, and Nothing but the Truth
During its brief history, Tesla (NASDAQ: TSLA) has missed many self-imposed deadlines to bring products to market. It has also routinely fallen short of its annual production goals. These shortcomings
Why Boeing Soared More Than 22% in July
Why Boeing Soared More Than 22% in July
Shares of Boeing (NYSE: BA) jumped 22.6% in July. Although shares had been trending upward since the beginning of the month, the biggest bump came in the wake of the company's impressive
Why Boeing Soared More Than 22% in July
Why Boeing Soared More Than 22% in July
Shares of Boeing (NYSE: BA) jumped 22.6% in July. Although shares had been trending upward since the beginning of the month, the biggest bump came in the wake of the company's impressive
How Safe Is Aflac's Dividend?
How Safe Is Aflac's Dividend?
Most Americans know Aflac (NYSE: AFL) because of its duck-filled ads on television, with the specialty insurer offering a different type of insurance coverage from what most people get through their
This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged
This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged
When it comes to the market's top-performing stocks, you'd have a hard time topping marijuana stocks over the trailing year. A majority of pot stocks over the past 12 months have at least doubled in
The 3 Best Buffett Stocks for Retirees
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
The 3 Best Buffett Stocks for Retirees
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
Why Consolidated Edison Is a Dividend Investor's Dream
Why Consolidated Edison Is a Dividend Investor's Dream
Let's face it: Utilities are no one's idea of an exciting class of stocks. This is perhaps why Consolidated Edison (NYSE: ED) seldom makes investors' lists of top 10 picks.That's too bad, because it's
Is This Why bluebird bio Dipped 10.5% in July?
Is This Why bluebird bio Dipped 10.5% in July?
bluebird bio (NASDAQ: BLUE), a clinical-stage biotech focused on gene therapy, fell more than 10% in July, according to S&P Global Market Intelligence. However, there wasn't any news released during
Why Twitter's Ad Revenue Won't Pick Up in the Second Half of 2017
Why Twitter's Ad Revenue Won't Pick Up in the Second Half of 2017
Twitter's (NYSE: TWTR) ad revenue has been in decline since the fourth quarter, and investors shouldn't expect that to change in the second half of the year, either. COO Anthony Noto told analysts on
Why Twitter's Ad Revenue Won't Pick Up in the Second Half of 2017
Why Twitter's Ad Revenue Won't Pick Up in the Second Half of 2017
Twitter's (NYSE: TWTR) ad revenue has been in decline since the fourth quarter, and investors shouldn't expect that to change in the second half of the year, either. COO Anthony Noto told analysts on
Why Twitter's Ad Revenue Won't Pick Up in the Second Half of 2017
Why Twitter's Ad Revenue Won't Pick Up in the Second Half of 2017
Twitter's (NYSE: TWTR) ad revenue has been in decline since the fourth quarter, and investors shouldn't expect that to change in the second half of the year, either. COO Anthony Noto told analysts on
Illumina Introduces a New Genomic Era
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic
Illumina Introduces a New Genomic Era
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic
Illumina Introduces a New Genomic Era
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Why BeiGene Soared 56.6% In July
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market
Why BeiGene Soared 56.6% In July
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market
Global Malware Attacks Hit Nuance's Results
Global Malware Attacks Hit Nuance's Results
Cyberattacks are becoming a fact of life, but they can have huge impacts on businesses. Nuance Communications (NASDAQ: NUAN) was a victim of June's NotPetya malware attack, and the incident took what
PRA Group Sees Volume Growth but Still Takes a Financial Hit
PRA Group Sees Volume Growth but Still Takes a Financial Hit
PRA Group (NASDAQ: PRAA) has worked hard to try to grow its debt-collection business, and a prosperous U.S. economy has made that effort tougher than one might think. Yet even when activity levels
Better Buy: PayPal Holdings, Inc. vs. Discover
Better Buy: PayPal Holdings, Inc. vs. Discover
The payments industry is quickly evolving, and while the credit card dynasties aren't going away anytime soon, there is competition from a new breed of payment companies. On one side of the ring is